Theranostics 2018; 8(20):5784-5800. doi:10.7150/thno.29035 This issue

Review

Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?

Jiaqiao Fan1✉, Dong Shang1, Bing Han2, Jianxun Song3, Hailong Chen1✉, Jin-Ming Yang4✉

1. Third General Surgery Department, The First Affiliated Hospital of Dalian Medical University, Dalian, China
2. Department of Pathology, College of Medicine, The Pennsylvania State University, Hershey, PA, USA
3. Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College Station, TX, USA
4. Department of Pharmacology, College of Medicine, The Pennsylvania State University, Hershey, PA, USA

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Fan J, Shang D, Han B, Song J, Chen H, Yang JM. Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?. Theranostics 2018; 8(20):5784-5800. doi:10.7150/thno.29035. Available from https://www.thno.org/v08p5784.htm

File import instruction

Abstract

Graphic abstract

The last decade has witnessed significant advances in the adoptive cell transfer (ACT) technique, which has been appreciated as one of the most promising treatments for patients with cancer. Utilization of ACT can enhance the function of the immune system or improve the specificity and persistence of transferred cells. Various immune cells including T lymphocytes, natural killer cells, dendritic cells, and even stem cells can be used in the ACT despite their different functional mechanisms. Colorectal cancer (CRC) is among the most common malignancies and causes millions of deaths worldwide every year. In this review, we discuss the status and perspective of the ACT in the treatment of CRC.

Keywords: adoptive cell transfer, immunotherapy, colorectal cancer